London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
And investment advice is Not investment advice
Sorry, typed too fast:
PCT is PCR
Remdisivir is Remdesivir
Nasalpharingal is Nasopharyngeal
St
TedB,
Hi. My opinion is the following: as much as there is a shift in the testing field, ie, from Nasalpharingal pct to LFA saliva quick test, now there seems to be a shift from injection to inhalation treatments. See Gilead shift to inhaled remdisivir.
In my opinion inhaled treatment is the way forward, hence my bet is on Gilead approaching SNG for combo inhaled therapy. Our CEO already said they would start talking to the FDA a while. I see smoke but it is my opinion and investment advice.
ST
Space, I thought that the WHO trial was Merck's Rebif. If the trial is succesful do you think they would then swop Rebif for SNG001?
..sorry, I have only upward thoughts with SNG.
spacetom: i was thinking laterally... was more interested in the who comment on interferon at the bottom than the hydroxychloriquinine and on the latter link, who is actually the competition and which of those who wish to operate in this space may be a purchaser of Syn. If you look at both together, then quite informative if you put the jigsaw pieces together. Was trying to work out who else to buy... sorry... lateral thought required.
....and the fact that interferon beta was kept in the solidarity WHO trial is a very good sign for me.
ST
Sparkle1,
Your post Drug Combos had to do with WHO solidarity trial, ie, the testing of 4 drugs either on their own or in combination. I replied on this post only and highlighted the fact that hydroxychloroquine and liponavir/ritonavir were abandoned, leaving only remdisivir and interferon beta in this solidarity trial.
ST
spacetomato... not entirely correct... this is the current list approved for trials : not many on it but it is current:
https://www.nihr.ac.uk/covid-studies/
Sparkle1 - in early July, both hydroxichloroquine and liponavir/ritonavir arms were dumped as proved non efficient. Only remaining contenders are remdesivir and interferon beta.
ST
This is what WHO decided to test back in January:
SARS-CoV-2 Drug Therapy
Drugs tested effective for SARS-CoV and/or MERS have been included in the WHO mega clinical trial – SOLIDARITY.31 For its study, WHO chose a nucleotide analogue Remdesivir; the malaria medication chloroquine (and its analog hydroxychloroquine); a combination of the anti-HIV drugs lopinavir and ritonavir; and that combination plus interferon-b.
Remdesivir is an antiviral prodrug of remdesivirtriphosphate with in vitro activity against coronaviruses.32,33 Remdesivir-TP acts as an inhibitor of RNA-dependent RNA polymerases and competes with adenosine-TP for incorporation into emerging viral RNA chains.34 Hydroxyhloroquine and chloroquine have in vitro activity against SARS-CoV-2 32,35 and the mechanism of action includes inhibition of viral enzymes (RNA polymerase), viral protein glycosylation, virus assembly, new virus particle transport, and virus release. Other mechanisms may also involve ACE2 receptor inhibition, decrease acidity in endosomes, and immunomodulation of cytokine release.5,32,36
The third arm of SOLIDARITY combines two HIV protease inhibitor drugs, lopinavir-ritonavir. The combination shown in vitro and in vivo potential activity for SARS-CoV and MERS-CoV 38,39 and the mechanism of action involves the inhibition of Mpro, an essential enzyme for coronavirus replication 40. Recent report published in The New England Journal of Medicine41 was not encouraging and the combination of lopinavir-ritonavir did not differ significantly from “standard care” group.
The fourth arm of SOLIDARITY combines lopinavir-ritonavir with interferon-b. The activation of innate antiviral response by interferon should have beneficial effects at least in the initial stage of infection. However, cautions should still be observed and the possibility that interferon might exacerbate inflammation during the late phase of SARS-CoV-2 infection cannot be excluded.